Lyra Therapeutics (LYRA) Total Current Liabilities (2019 - 2025)
Quarterly Total Current Liabilities fell 24.61% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 24.61% year-over-year, with the annual reading at $9.5 million for FY2025, 24.61% down from the prior year.
Lyra Therapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $9.5 million for Q4 2025.
- Total Current Liabilities came in at $9.5 million for Q4 2025, roughly flat from $9.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $22.0 million in Q1 2022 to a low of $4.2 million in Q1 2021.
- The 5-year median for Total Current Liabilities is $14.1 million (2023), against an average of $14.1 million.
- Year-over-year, Total Current Liabilities surged 426.74% in 2022 and then plummeted 42.09% in 2025.
- Lyra Therapeutics' Total Current Liabilities stood at $18.2 million in 2021, then decreased by 20.69% to $14.5 million in 2022, then soared by 35.43% to $19.6 million in 2023, then tumbled by 35.55% to $12.6 million in 2024, then fell by 24.61% to $9.5 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Total Current Liabilities are $9.5 million (Q4 2025), $9.5 million (Q3 2025), and $11.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Lyra Therapeutics | - | - | - | 9.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.52 Mn |
| Sep 30, 2025 | 9.48 Mn |
| Jun 30, 2025 | 11.16 Mn |
| Mar 31, 2025 | 11.47 Mn |
| Dec 31, 2024 | 12.63 Mn |
| Sep 30, 2024 | 14.95 Mn |
| Jun 30, 2024 | 19.28 Mn |
| Mar 31, 2024 | 18.72 Mn |
| Dec 31, 2023 | 19.60 Mn |
| Sep 30, 2023 | 19.24 Mn |
| Jun 30, 2023 | 14.11 Mn |
| Mar 31, 2023 | 14.15 Mn |
| Dec 31, 2022 | 14.47 Mn |
| Sep 30, 2022 | 13.61 Mn |
| Jun 30, 2022 | 10.61 Mn |
| Mar 31, 2022 | 21.97 Mn |
| Dec 31, 2021 | 18.25 Mn |
| Sep 30, 2021 | 17.77 Mn |
| Jun 30, 2021 | 5.90 Mn |
| Mar 31, 2021 | 4.17 Mn |
| Dec 31, 2020 | 4.88 Mn |
| Sep 30, 2020 | 4.71 Mn |
| Jun 30, 2020 | 3.94 Mn |
| Mar 31, 2020 | 5.16 Mn |
| Dec 31, 2019 | 5.21 Mn |